Product Description
Novartis is developing a FAP Radioligand Therapy for patients with solid tumors. (Sourced from: https://clinicaltrials.gov/study/NCT04939610)
Mechanisms of Action: Radioligand Therapy, FAP
Novel Mechanism: Yes
Modality: Radioligand Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, France, Italy, Spain, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Breast Cancer|Ductal Breast Carcinoma|Mesothelioma|Non-Small-Cell Lung Cancer|Oncology Unspecified|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Small Cell Lung Cancer|Small Cell Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07434180 |
Lu-FAP CUP | P2 |
Not yet recruiting |
Oncology Unspecified |
2030-06-01 |
12% |
2026-02-26 |
Primary Endpoints|Treatments |
NCT04939610 |
LuMIERE | P2 |
Recruiting |
Pancreatic Cancer|Pancreatic Ductal Carcinoma|Mesothelioma|Non-Small-Cell Lung Cancer|Small Cell Sarcoma|Small Cell Lung Cancer|Breast Cancer|Ductal Breast Carcinoma|Adenocarcinoma |
2027-12-31 |
28% |
2026-07-25 |
|
2023-508995-12-01 |
CAAA614A12101 | P2 |
Not yet recruiting |
Pancreatic Ductal Carcinoma|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Adenocarcinoma|Ductal Breast Carcinoma|Breast Cancer |
2032-10-15 |
Recent News Events
Date |
Type |
Title |
|---|